LEXINGTON, Mass., May 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that the Company will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on May 19, 2008 at 4:55 p.m. local time (10:55 a.m. EDT) and at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference on Thursday, May 29, 2008 at 10:00 a.m. local time (5:00 a.m. EDT). The presentations will be web cast live and may be accessed by visiting the Investors section of the Indevus website at http://www.indevus.com.
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable ureteral stent used in association with the adjunctive treatment of kidney stones.
Forward Looking Statements
Except for the descriptions of historical facts contained herein, this
press release contains forward-looking statements that involve risks and
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved